Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Highlights

Highlights of This Issue

DOI:  Published July 2011
  • Article
  • Info & Metrics
  • PDF
Loading

Sorafenib Enhances Antitumor Effects of Chemoradiation

Yadav et al., Page 1241

Concurrent chemoradiation is one of the widely used treatments for head and neck cancer, but it is often unsuccessful due to the development of chemo- and radioresistance. In this report, Yadav and colleagues demonstrate that sorafenib can enhance the therapeutic efficacy of chemoradiation treatment by sensitizing tumor cells via the downregulation of DNA repair proteins (ERCC-1 and XRCC-1) and also by decreasing tumor angiogenesis by blocking VEGF-mediated signaling. This strategy of combining low doses of sorafenib along with chemoradiation has the potential of significantly decreasing side effects associated with the current standard chemoradiation treatment while maintaining its therapeutic efficacy.

Time-Course Functional Imaging of Antiangiogenic Therapy

Zhang et al., Page 1173

The vasculature and blood flow in tumors are highly heterogeneous. The ability to image in real time the effects of antiangiogenic agents on vascular structure and function in tumors would greatly improve our knowledge on the mechanism of such agents and enable discovery of more effective ones. Zhang and colleagues have developed a new technology that enables variable-magnification in vivo fluorescence imaging as well as fluorescence tomography to visualize functional normalization of tumor blood vessels by antiangiogenic agents in real time. The results of this study also characterize the role of tumor vascular normalization in enhanced chemotherapeutic drug delivery and antitumor efficacy.

Oncogenic Activity of the Novel TRIM59 Gene

Valiyeva et al., Page 1229

A novel TRIM gene family member, TRIM59, was found to be upregulated in SV40 Tag oncogene-directed transgenic and knockout mouse prostate cancer (CaP) models. Two phosphorylated forms of TRIM59 were characterized to be correlated with tumorigenesis and the advanced CaP. Short hairpin RNA-mediated knockdown of TRIM59 caused S phase cell cycle and growth arrest, along with a hit-and-run effect implicating that the initial knockdown occurred early in the Ras signaling pathway. Transgenic mouse model upregulating the TRIM59 gene in the prostate revealed the proto-oncogenic activity in tumorigenesis and progression coincided with the upregulation of genes bridging between Ras and SV40Tag signaling pathways. The finding of a possible novel oncogene in animal models will implicate a novel strategy for diagnosis, prognosis, and therapy of cancer.

Chemotherapy Schedule Influences Drug Resistance

De Souza et al., Page 1289

Drug resistance is the major cause of chemotherapy failure in ovarian cancer. De Souza and colleagues have shown that changes to the chemotherapy dosing schedule significantly affect drug resistance. Elimination of treatment-free intervals via continuous chemotherapy of the drug docetaxel resulted in greater antitumor efficacy than intermittent (once or three times weekly) dosing in chemosensitive and chemoresistant ovarian cancer models and did not induce upregulation of genes implicated in docetaxel resistance, whereas significant upregulation resulted from intermittent administration. This supports the clinical implementation of more frequent dosing schedules in the treatment of solid tumors such as ovarian cancer.

  • ©2011 American Association for Cancer Research.
PreviousNext
Back to top
Molecular Cancer Therapeutics: 10 (7)
July 2011
Volume 10, Issue 7
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Highlights of This Issue
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Highlights of This Issue
Mol Cancer Ther July 1 2011 (10) (7) 1125;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Highlights of This Issue
Mol Cancer Ther July 1 2011 (10) (7) 1125;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Sorafenib Enhances Antitumor Effects of Chemoradiation
    • Time-Course Functional Imaging of Antiangiogenic Therapy
    • Oncogenic Activity of the Novel TRIM59 Gene
    • Chemotherapy Schedule Influences Drug Resistance
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Selected Articles from This Issue
  • Selected Articles from This Issue
  • Selected Articles from This Issue
Show more Highlights
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement